Bausch Health pipeline, including Duobrii, ‘not impressive’: Wells Fargo

After Bausch Health (BHC) announced the “delayed approval” of Duobrii, Wells Fargo analyst David Maris said that he thinks that the drug, which combines two generic ingredients, “may be attractive to some patients, [but] we do not believe that these types of non-NCE products are attractive to payors.” Bausch’s drug pipeline, including Duobrii, “is not impressive and this approval is only meaningful as it now allows us to track another drug,” stated Maris, who keeps an Underperform rating on the stock. He also noted that Bausch separately announced that it in-licensed a drug Biogen (BIIB) had previously in-licensed and sent back to Tanabe, telling investors that he is skeptical of MT-1303 “for a variety of reasons beyond it having already had one partner return it.”

https://thefly.com/landingPageNews.php?id=2897807